

### REMARKS/ARGUMENTS

Claims 10-11, 13, 34-39, 43, 45-47, 50-54, 58, 62-65 and 73-112 were pending before entry of this amendment. In this amendment, claims 45-47, 50-54, 58, 62, 63, 73, 75 are canceled without prejudice or disclaimer. Accordingly, after entry of this amendment claims 10-11, 13, 34-39, 43, 64-65, 74 and 76-112 will be pending. Applicants reserve the right to pursue the subject matter of the canceled claims in continuing applications.

A requirement for unity of invention in the above-identified application was mailed on August 14, 2009, dividing the pending claims into eleven groups as follows:

- I. Claims 10-11, 13, 77 and 79-106, drawn to an antibody, comprising points of conjugation for a cytotoxic or cytostatic agent, wherein at least one point of conjugation for the cytotoxic or cytostatic agent on the antibody can be readily assigned, and wherein less than all possible points of conjugation are available for conjugation to the cytotoxic or cytostatic agent.
- II. Claims 34-39, 43, 45-47, 50-54, 58, 62-65 and 73-75, drawn to a method of reducing and conjugating a drug to an antibody.
- III. Claims 73-74, drawn to a method for a conjugate of a protein other than antibody having one or more disulfide bonds and a drug.
- IV. Claims 77, 84, 86 and 93, drawn to a partially loaded, modified protein, the modified protein is a specific receptor.
- V. Claims 77, 84, 86 and 93, drawn to a partially loaded, modified protein, the modified protein is a specific receptor ligand.
- VI. Claims 77, 84, 86 and 93, drawn to a partially loaded, modified protein, the modified protein is a specific hormone.

- VII. Claims 77, 84, 86 and 93, drawn to a partially loaded, modified protein, the modified protein is a specific cytokine.
- VIII. Claims 107-112, drawn to a method for the treatment of cancer in a patient, comprising administering to the patient an amount of a specific modified antibody.
- IX. Claims 107-112, drawn to a method for the treatment of a specific immune disease other than autoimmune disease in a patient, comprising administering to the patient an amount of a specific modified antibody.
- X. Claims 107-112, drawn to a method for the treatment of a specific autoimmune disease in a patient, comprising administering to the patient an amount of a specific modified antibody.
- XI. Claims 107-112, drawn to a method for the treatment of a specific infectious disease in a patient, comprising administering to the patient an amount of a specific modified antibody.

The requirement also acknowledges that linking claims 76 and 78 link Groups I, IV, VI and VII.

Although they do not agree with the holding of a lack of unity, in order to expedite prosecution Applicants hereby elect Group II, with traverse. Claims 34 -39, 43, 64-65, and 74 are readable upon the elected Group II.

### CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-752-2465.

Respectfully submitted,

/Ashita A. Doshi/ Reg. No. 57,327

Ashita A. Doshi  
Reg. No. 57,327

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 415-576-0300  
Attachments  
AAD:rcw  
62211011 v2